Different mechanisms of secondary resistance can occur in patients treated with osimertinib and may be detected with a LB, such as the emergence of a small tumor cell subpopulation carrying the EGFR-C797S mutation, an additional subpopulation carrying amplified copies of EGFR-exon19del or other genomic alterations [10,41]. The gene discussed is EGFR; the disease is neoplasm.